United States Patent 9,012,462: A Detailed Analysis of Scope, Claims, and Patent Landscape
Overview of the Patent
United States Patent 9,012,462, titled "Phosphorous Derivatives as Kinase Inhibitors," was granted to ARIAD Pharmaceuticals, Inc. on April 21, 2015. This patent is significant in the field of pharmaceuticals, particularly in the development of kinase inhibitors.
Inventors and Assignees
The patent was invented by Yihan Wang, Newton, MA; Wei-Sheng Huang, Acton, MA; Shuangying Liu, Wellesley, MA; William C. Shakespeare, Southborough, MA; and R. Mathew Thomas, Sharon, MA. The assignee is ARIAD Pharmaceuticals, Inc.[2][5].
Scope of the Patent
The patent covers a class of compounds known as phosphorous derivatives, which are designed to act as kinase inhibitors. Kinases are enzymes that play crucial roles in various cellular processes, including cell signaling pathways. The inhibition of specific kinases is a key strategy in treating diseases such as cancer.
Chemical Structure
The patented compounds are described by a general formula (I), which includes various substituents and moieties. For example, the compounds may include phenyl, diamine, dimethylphosphoryl, and other functional groups. The specific chemical structures, such as 5-chloro-2-n-(4-dimethylphosphoryl-2-methylphenyl)-4-n-(2-propan-2-ylsulfonylphenyl)pyrimidine-2,4-diamine, are detailed in the patent documentation[1][2].
Claims
The patent includes multiple claims that define the scope of protection for the invented compounds and their uses.
Composition of Matter Claims
These claims cover the specific chemical compounds and their derivatives. The patent protects the composition of matter of these phosphorous derivatives, ensuring that ARIAD Pharmaceuticals has exclusive rights to these compounds until the patent expires[1][5].
Method of Use Claims
In addition to composition of matter claims, the patent also includes method of use claims. These claims cover the use of the phosphorous derivatives as kinase inhibitors in therapeutic applications, particularly in the treatment of diseases such as cancer[1][2].
Patent Landscape
The issuance of this patent is part of a broader landscape of patent activity in the pharmaceutical industry, particularly in the area of kinase inhibitors.
Related Patents and Applications
The patent is linked to several other patent applications and granted patents in the same field. For instance, other patents and applications related to kinase inhibitors, such as those covering brigatinib (an ALK inhibitor), are also part of ARIAD Pharmaceuticals' intellectual property portfolio[5].
Exclusivity and Protection
The patent provides composition-of-matter protection for ARIAD’s investigational ALK inhibitor, brigatinib, through at least December 30, 2030. This exclusivity is crucial for the commercialization and development of brigatinib as a therapeutic agent[5].
Therapeutic Applications
The phosphorous derivatives covered by this patent are intended for use in treating various diseases, particularly those involving aberrant kinase activity.
Cancer Treatment
Kinase inhibitors are a cornerstone in cancer therapy, targeting specific kinases that are overactive or mutated in cancer cells. The patented compounds are designed to inhibit these kinases, thereby halting or slowing the progression of cancer[1][4].
Industry Impact
The issuance of this patent has significant implications for the pharmaceutical industry.
Competitive Advantage
ARIAD Pharmaceuticals gains a competitive advantage through the exclusive rights granted by this patent. This allows the company to develop and market brigatinib without competition from generic or similar products until the patent expires[5].
Research and Development
The patent also encourages further research and development in the field of kinase inhibitors. By protecting the intellectual property of these compounds, the patent incentivizes innovation and investment in pharmaceutical research[3].
Key Takeaways
- Patent Scope: The patent covers phosphorous derivatives as kinase inhibitors, including specific chemical structures and their therapeutic uses.
- Claims: The patent includes composition of matter and method of use claims, providing broad protection for the invented compounds.
- Patent Landscape: The patent is part of a larger landscape of patent activity in kinase inhibitors, with related patents and applications covering other therapeutic agents.
- Exclusivity: The patent provides exclusivity for ARIAD Pharmaceuticals’ brigatinib through at least December 30, 2030.
- Therapeutic Applications: The patented compounds are primarily used in cancer treatment by inhibiting specific kinases.
FAQs
What is the main subject of United States Patent 9,012,462?
The main subject of this patent is phosphorous derivatives that act as kinase inhibitors.
Who are the inventors of this patent?
The inventors include Yihan Wang, Wei-Sheng Huang, Shuangying Liu, William C. Shakespeare, and R. Mathew Thomas.
What is the assignee of this patent?
The assignee is ARIAD Pharmaceuticals, Inc.
What is the therapeutic application of the patented compounds?
The compounds are primarily used in the treatment of diseases such as cancer by inhibiting specific kinases.
How long does the patent provide exclusivity for brigatinib?
The patent provides exclusivity for brigatinib through at least December 30, 2030.
What is the significance of this patent in the pharmaceutical industry?
This patent provides ARIAD Pharmaceuticals with a competitive advantage and encourages further research and development in kinase inhibitors.
Sources
- US9012462B2 - Phosphorous derivatives as kinase inhibitors - Google Patents
- (12) United States Patent (10) Patent No.: US 9,012,462 B2 - googleapis.com
- A novel approach to understand patents from the drug discovery ... - biorxiv.org
- (12) United States Patent - googleapis.com
- ARIAD Announces Issuance of Key U.S. Patent on Brigatinib - businesswire.com
